Agenus Inc (AGEN)
6.26
+0.49
(+8.49%)
USD |
NASDAQ |
Apr 23, 11:07
Agenus SG&A Expense (Quarterly): 21.18M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 21.18M |
September 30, 2023 | 18.91M |
June 30, 2023 | 20.42M |
March 31, 2023 | 18.24M |
December 31, 2022 | 25.04M |
September 30, 2022 | 18.10M |
June 30, 2022 | 18.91M |
March 31, 2022 | 18.95M |
December 31, 2021 | 21.97M |
September 30, 2021 | 21.38M |
June 30, 2021 | 16.65M |
March 31, 2021 | 16.35M |
December 31, 2020 | 20.03M |
September 30, 2020 | 14.38M |
June 30, 2020 | 14.20M |
March 31, 2020 | 10.61M |
December 31, 2019 | 12.32M |
September 30, 2019 | 11.51M |
June 30, 2019 | 11.40M |
March 31, 2019 | 10.80M |
December 31, 2018 | 9.724M |
September 30, 2018 | 9.203M |
June 30, 2018 | 9.485M |
March 31, 2018 | 8.928M |
December 31, 2017 | 9.784M |
Date | Value |
---|---|
September 30, 2017 | 8.051M |
June 30, 2017 | 8.136M |
March 31, 2017 | 7.770M |
December 31, 2016 | 8.670M |
September 30, 2016 | 8.107M |
June 30, 2016 | 7.117M |
March 31, 2016 | 9.232M |
December 31, 2015 | 8.459M |
September 30, 2015 | 6.408M |
June 30, 2015 | 8.016M |
March 31, 2015 | 5.487M |
December 31, 2014 | 5.040M |
September 30, 2014 | 4.920M |
June 30, 2014 | 6.127M |
March 31, 2014 | 5.164M |
December 31, 2013 | 3.372M |
September 30, 2013 | 3.578M |
June 30, 2013 | 4.642M |
March 31, 2013 | 2.892M |
December 31, 2012 | 2.646M |
September 30, 2012 | 2.587M |
June 30, 2012 | 3.359M |
March 31, 2012 | 2.874M |
December 31, 2011 | 2.71M |
September 30, 2011 | 2.567M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
10.61M
Minimum
Mar 2020
25.04M
Maximum
Dec 2022
17.40M
Average
18.24M
Median
Mar 2023
SG&A Expense (Quarterly) Benchmarks
Protalix BioTherapeutics Inc | 4.143M |
InfuSystems Holdings Inc | 13.26M |
PAVmed Inc | 11.72M |
Allogene Therapeutics Inc | 17.22M |
Pfizer Inc | 4.575B |